BTBP(SH:600161) Sou Hu Cai Jing·2025-08-12 10:47Company Performance - Tian Tan Biological reported a total revenue of 1.318 billion yuan for Q1 2025, representing a year-on-year growth of 7.84% [1] - The net profit attributable to shareholders was 244 million yuan, a decrease of 22.90% year-on-year [1] - The non-recurring net profit was 239 million yuan, down 23.71% year-on-year [1] - The current ratio was 7.188, the quick ratio was 3.627, and the debt-to-asset ratio was 8.41% [1] Stock Market Activity - As of August 12, 2025, Tian Tan Biological's stock closed at 20.45 yuan, down 0.1% [1] - The trading volume was 188,500 lots, with a total transaction amount of 386 million yuan [1] - There was a net outflow of main funds amounting to 17.18 million yuan, accounting for 4.45% of the transaction amount [1] - Large orders saw a net outflow of 19.29 million yuan, while small orders had a net inflow of 8.11 million yuan [1] Company Background - Beijing Tian Tan Biological Products Co., Ltd. was established in 1998 and is located in Beijing, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 1.977 billion yuan and a paid-in capital of 1.977 billion yuan [1] - The legal representative of the company is Wei Yanlin [1] Investment and Intellectual Property - The company has made investments in 4 enterprises and participated in 1,165 bidding projects [2] - Tian Tan Biological holds 102 trademark registrations and 3 patents, along with 9 administrative licenses [2]